Immunic, Inc.
IMUX
$0.72
-$0.0264-3.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.64% | 12.48% | 16.46% | 14.14% | 8.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.37% | -1.18% | -4.39% | -3.20% | 3.81% |
| Operating Income | -5.37% | 1.18% | 4.39% | 3.20% | -3.81% |
| Income Before Tax | 1.56% | -7.37% | 24.60% | 24.94% | 21.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.56% | -7.37% | 24.60% | 24.94% | 21.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.56% | -7.37% | 24.60% | 24.94% | 21.58% |
| EBIT | -5.37% | 1.18% | 4.39% | 3.20% | -3.81% |
| EBITDA | -5.32% | 1.20% | 4.41% | 3.23% | -3.80% |
| EPS Basic | 48.16% | 52.41% | 60.07% | 54.08% | 47.04% |
| Normalized Basic EPS | 47.68% | 54.75% | 46.95% | 39.83% | 31.46% |
| EPS Diluted | 48.16% | 52.41% | 60.07% | 54.08% | 47.04% |
| Normalized Diluted EPS | 47.68% | 54.75% | 46.95% | 39.83% | 31.46% |
| Average Basic Shares Outstanding | 75.22% | 125.95% | 101.45% | 83.31% | 61.71% |
| Average Diluted Shares Outstanding | 75.22% | 125.95% | 101.45% | 83.31% | 61.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |